LOS ANGELES -- (Business Wire)
Lundin Law PC announces it is investigating claims against Osiris
Therapeutics, Inc. (“Osiris” or the “Company”) (NASDAQ: OSIR)
concerning possible violations of federal securities laws. The
investigation is related to allegations that certain statements issued
by Osiris were false and misleading and/or failed to disclose material
information regarding the Company’s financial performance.
To participate in this class action lawsuit, please contact Brian
Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.
The investigation will focus on the Company’s announcement that it has
determined to correct the revenue recognition for three contracts which
will result in a decrease in product revenues of $1.8 million in the
first quarter of 2015, a decrease in product revenues of $1.0 million in
the second quarter, an increase in product revenues of $0.8 million in
the third quarter of 2015 and a decrease in product revenues of $1.1
million in 2014. When the truth was revealed, shares dropped causing
investors harm.
No class has been certified in the above action. Until a class is
certified, you are not considered represented by an attorney. You may
also choose to do nothing and be an absent class member.
Lundin Law PC was created by Brian Lundin, a securities litigator based
in Los Angeles.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005530/en/
Contacts:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile:
888-713-1125
brian@lundinlaw.com
Source: Lundin Law PC
© 2024 Canjex Publishing Ltd. All rights reserved.